Предиктивные маркёры развития иммуноопосредованных нежелательных явлений

Standard

Предиктивные маркёры развития иммуноопосредованных нежелательных явлений. / Zhukova, N. V.; Orlova, R. V.; Malkova, A. M.; Kaledina, E. A.; Belyak, N. P.

In: Вопросы онкологии, Vol. 68, No. 1, 01.01.2022, p. 29-33.

Research output: Contribution to journal › Article › peer-review

BibTeX

@article{69bd72eac64240518d98fd4ab348d536,

title = "Предиктивные маркёры развития иммуноопосредованных нежелательных явлений",

abstract = "Taking into account widespread use of check-point inhibitors in real clinical practice, pharmacoeconomic issues, the incidence and grade of immune-related adverse events, there is an urgent need for using prognostic and predictive biomarkers of toxicity of immunotherapy. This review presents a literature review of the databases such as PubMed, MEDLINE, Google Scholar, Springer. Articles were searched using the keywords: «predictive biomarkers of toxicity», «immunotherapy», «predictive markers of immune-related adverse events». Subsequently the information obtained was analyzed in order to define possible predictive biomarkers of immune-related toxicity that could be used in real clinical practice.",

keywords = "check-point inhibitors, gut microbiota, HLA-genotypes, IL-10, immune-related adverse events (IRAEs), immunotherapy, predictive biomarkers, review",

author = "Zhukova, {N. V.} and Orlova, {R. V.} and Malkova, {A. M.} and Kaledina, {E. A.} and Belyak, {N. P.}",

year = "2022",

month = jan,

day = "1",

doi = "10.37469/0507-3758-2022-68-1-29-33",

language = "русский",

volume = "68",

pages = "29--33",

journal = "Вопросы онкологии",

issn = "0507-3758",

publisher = "Медицина",

number = "1",

}

RIS

TY - JOUR

T1 - Предиктивные маркёры развития иммуноопосредованных нежелательных явлений

AU - Zhukova, N. V.

AU - Orlova, R. V.

AU - Malkova, A. M.

AU - Kaledina, E. A.

AU - Belyak, N. P.

PY - 2022/1/1

Y1 - 2022/1/1

N2 - Taking into account widespread use of check-point inhibitors in real clinical practice, pharmacoeconomic issues, the incidence and grade of immune-related adverse events, there is an urgent need for using prognostic and predictive biomarkers of toxicity of immunotherapy. This review presents a literature review of the databases such as PubMed, MEDLINE, Google Scholar, Springer. Articles were searched using the keywords: «predictive biomarkers of toxicity», «immunotherapy», «predictive markers of immune-related adverse events». Subsequently the information obtained was analyzed in order to define possible predictive biomarkers of immune-related toxicity that could be used in real clinical practice.

AB - Taking into account widespread use of check-point inhibitors in real clinical practice, pharmacoeconomic issues, the incidence and grade of immune-related adverse events, there is an urgent need for using prognostic and predictive biomarkers of toxicity of immunotherapy. This review presents a literature review of the databases such as PubMed, MEDLINE, Google Scholar, Springer. Articles were searched using the keywords: «predictive biomarkers of toxicity», «immunotherapy», «predictive markers of immune-related adverse events». Subsequently the information obtained was analyzed in order to define possible predictive biomarkers of immune-related toxicity that could be used in real clinical practice.

KW - check-point inhibitors

KW - gut microbiota

KW - HLA-genotypes

KW - IL-10

KW - immune-related adverse events (IRAEs)

KW - immunotherapy

KW - predictive biomarkers

KW - review

UR - http://www.scopus.com/inward/record.url?scp=85135326028&partnerID=8YFLogxK

U2 - 10.37469/0507-3758-2022-68-1-29-33

DO - 10.37469/0507-3758-2022-68-1-29-33

M3 - статья

AN - SCOPUS:85135326028

VL - 68

SP - 29

EP - 33

JO - Вопросы онкологии

JF - Вопросы онкологии

SN - 0507-3758

IS - 1

ER -

ID: 116163778